S. Karger AG

SHERPA: Unknown

People

  1. Bodei
    Bodei
  2. Drilon
    Drilon
  3. Motzer
    Motzer
  4. Abou-Alfa
    Abou-Alfa
  5. Chaganti
    Chaganti
  6. Lin
    Lin
  7. Tang
    Tang
  8. Clarkson
    Clarkson
  9. Janjigian
    Janjigian
  10. Marghoob
    Marghoob

Groups

  1. Department of Medicine (279)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)
  7. Sloan Kettering Institute Postdocs (55)
  8. Surgery (54)
  9. Sloan Kettering Institute Faculty (47)
  10. Thoracic Oncology (45)
Search Within
Formats
  1. Meeting Abstract (332)
  2. Journal Article (254)
  3. Book Section (20)
  4. Review (15)
  5. Conference Paper (10)
  6. Book Whole (1)
  7. Editorial (1)
Groups
  1. Department of Medicine (279)
  2. Solid Tumor Oncology Division (160)
  3. Hematologic Malignancies, Division of (107)
  4. Center for Hematologic Malignancies (103)
  5. Survivorship Research (59)
  6. Gastrointestinal Oncology Service (57)

More Groups

People
  1. Lisa Bodei (32)
  2. Alexander Drilon (23)
  3. Robert Motzer (23)
  4. Ghassan Abou-Alfa (18)
  5. Steven Hajdu (18)
  6. Oscar Lin (16)

More People

Years
  1. 2025 (3)
  2. 2024 (21)
  3. 2023 (37)
  4. 2022 (42)
  5. 2021 (31)
  6. 2020 (51)

More Years

Publications
  1. Oncology Research and Treatment (226)
  2. Cytogenetics and Cell Genetics (61)
  3. Acta Cytologica (58)
  4. Neuroendocrinology (51)
  5. Acta Haematologica (32)
  6. Onkologie (19)

More Publications

Results (633)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood
    Meeting Abstract

    Oberg, K.; Califano, A.; Strosberg, J.; Ma, S.; Pape, U. F.; Bodei, L.; Kaltsas, G.; Toumpanakis, C.; Goldenring, J.; Frilling, A.; more...
    Neuroendocrinology (2020)

    Fulltext@MSK | Save
  • PRRT neuroendocrine tumor response assessment using circulating transcript analysis: The NETest
    Meeting Abstract

    Bodei, L.; Kidd, M.; Singh, A.; van der Zwan, V.; Severi, S.; Drozdov, I.; Malczewska, A.; Baum, R. P.; Kwekkeboom, D.; Paganelli, G.; more...
    Neuroendocrinology (2020)

    Fulltext@MSK | Save
  • Integrative genomic characterization identifies molecular subtypes of lung carcinoids
    Meeting Abstract

    Laddha, S. V.; da Silva, E. M.; Robzyk, K.; Untch, B. R.; Ke, H.; Rekhtman, N.; Poirier, J. T.; Travis, W. D.; Tang, L. H.; Chan, C. S.
    Neuroendocrinology (2020)

    Fulltext@MSK | Save
  • Nivolumab (N) plus low-dose ipilimumab (I) vs platinum-doublet chemotherapy (Chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): Checkmate 227 part 1 final analysis
    Meeting Abstract

    Reck, M.; Peters, S.; Ramalingam, S.; Paz-Ares, L.; Caro, R. B.; Zurawski, B.; Kim, S. W.; Alexandru, A.; Lupinacci, L.; Jitnenez, E. D.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Entrectinib in locally advanced / metastatic ROS1 and NTRK fusion-positive (NTRK plus ) non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    Meeting Abstract

    Springfeld, C.; de Braude, F.; Siena, S.; Barlesi, F.; Drilon, A.; Simmons, B.; Huang, X.; Pitcher, B.; Doebele, R. C.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Entrectinib in patients with NTRK fusion-positive solid tumors or ROS1-positive NSCLC with CNS metastases
    Meeting Abstract

    Paz-Ares, L.; Dziadziuszko, R.; Drilon, A.; John, T.; Krebs, M.; Demetri, G.; Shaw, A. T.; Siena, S.; Wolf, J.; Farago, A. F.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Fight-202: A phase 2 study of pemigatinib in patients (PTS) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)
    Meeting Abstract

    Vogel, A.; Sahai, V.; Hollebecque, A.; Vaccaro, G.; Melisi, D.; Al-Rajabi, R.; Paulson, A. S.; Borad, M. J.; Gallinson, D.; Murphy, A. G.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Genomic landscape of entrectinib resistance from circulating tumor DNA (CTDNA) analysis in STARTRK-2
    Meeting Abstract

    Doebele, R. C.; Dziadziuszko, R.; Drilon, A.; Shaw, A. T.; Wolf, J.; Farago, A. F.; Dennis, L.; Riehl, T.; Simmons, B.; Wu, C.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Depth of response (DEPOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101
    Meeting Abstract

    Voss, M. H.; Motzer, R. J.; Albiges, L.; Rini, B.I.; Schmidinger, M.; Larkin, J.; Haanen, J. B. A. G.; Kollmannsberger, C.; Campbell, M. T.; Pal, S. K.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Safety and efficacy results from Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) In relapsed/refractory (R/R) large B-cell lymphoma (LBCL)
    Meeting Abstract

    Abramson, J.; Palomba, M. L.; Gordon, L.; Lunning, M.; Wang, M.; Arnason, J.; Mehta, A.; Purev, E.; Maloney, D.; Andreadis, C.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save